AR045388A1 - Inhibidores del c-kit imidazopiridinicos n3-sustituidos - Google Patents
Inhibidores del c-kit imidazopiridinicos n3-sustituidosInfo
- Publication number
- AR045388A1 AR045388A1 ARP040103009A ARP040103009A AR045388A1 AR 045388 A1 AR045388 A1 AR 045388A1 AR P040103009 A ARP040103009 A AR P040103009A AR P040103009 A ARP040103009 A AR P040103009A AR 045388 A1 AR045388 A1 AR 045388A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cyclyl
- heterocyclyl
- nr3r31
- nr3c
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a inhibidores del c-kit imidazopiridinicos N3-sustituidos, o sales o N-óxidos aceptables para uso farmacéutico, útiles en el tratamiento del cáncer. Reivindicación 1: Un compuesto representado por la fórmula (1) en la cual R1 es: -NR3R31, -NR3C(O)R31, -NR3C(O)OR31, -NR3SO2R31, -OR3, -SR3, -SO2R3, -CO2R3, -CO2H, -CO-NR3R31, -N(alquilo C0-8)(alquilo C0-8), o -CN; excepto que cuando Y está presente y m> 1, entonces R1 es halógeno, -CN, NO2, -alquilo C0-8, -N(alquilo C0-8)(alquilo C0-8), alquenilo C2-8, alquinilo C2-8, -NR3R31, NR3C(O)R31, -NR3C(O)OR31, -NR3SO2R31, -OR3, -SR3, -SO2R3, -CO2R3, -CO2H, -CO-NR3R31, ciclilo, o un grupo heterociclilo; R2 es H, -alquilo C0-8, o -cicloalquilo C3-10; X es un grupo ciclilo o heterociclilo opcionalmente sustituido con uno o más sustituyentes elegidos de H, halógeno, NR32R33, -NR32COR33, -NR32CO2R33, -NR32SO2R33, -OR32, -SR32, -SO2R32, -SO2NR32R33, -CO2R32, -CO2H, -CONR32R33, -alquilo C0-8, -alquenilo C2-8, -alquinilo C2-8, -CN, -CF3, -OCF3, -NO2, oxo, ciclilo o un grupo heterociclilo, Y está ausente, o es uno de los grupos de fórmulas (2) en donde el punto de unión a X puede estar tanto a la izquierda como a la derecha de los conectores como se muestra; Ra y Rb cada uno independientemente es -alquilo C0-8 -alquenilo C2-8, -alquinilo C2-8, cicloalquilo C3-10, -cicloalquenilo C3-10, -alcoxi C1-8, -tioalquilo C1-8, carboxilo, -N(alquilo C0-8)(alquilo C0-8), oxo, o hidroxi; o tomados junto con el C al cual están unidos forman un anillo de 3-10 miembros saturado o parcialmente insaturado que contiene opcionalmente 0-4 N, O, S, SO, o SO2 en los nodos del anillo; Rc y Rd cada uno independientemente es -alquilo C0-8; -alquenilo C2-8, bencilo, o acilo; o tomados juntos, o con Ra o Rb, forman un anillo de 3-7 miembros saturado o parcialmente insaturado; m es 0,1 2, 3, 4 o 5; Z es un grupo ciclilo o heterociclilo, opcionalmente sustituido con uno o más sustituyentes elegidos de halógeno, un grupo NR34R35, NR34COR35, NR34CO2R35, NR34SO2R35, OR34, SR34, SO2R34, SO2NR34R35, CO2R34, CO2H, CONR34R35, alquil C0-8, alquenilo C2-8, alquinilo C2-8, CN, CF3, NO2, oxo, ciclilo o heterociclilo; o, cuando X e Y están presentes, Z puede ser -alquilo C1-8 o -alquilo C1-8-O-alquilo C1-8, y R3, R31, R32, R33, R34 y R35 son independientemente alquilo C0-8 opcionalmente sustituido con un sustituyente heterociclilo o OH; -alquilo C0-8-cicloalquilo C3-8, CF3,-alquilo C0-8-O-alquilo C0-8, -alquilo C0-8-N(alquilo C0-8)(alquilo C0-8), -alquilo C0-8-S(O)0-2-alquilo C0-8 o heterociclilo opcionalmente sustituido con -alquilo C0-8, ciclilo o sustituyente ciclilo sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49677603P | 2003-08-21 | 2003-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045388A1 true AR045388A1 (es) | 2005-10-26 |
Family
ID=34272515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103009A AR045388A1 (es) | 2003-08-21 | 2004-08-20 | Inhibidores del c-kit imidazopiridinicos n3-sustituidos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1658289B1 (es) |
| JP (1) | JP2007502822A (es) |
| KR (1) | KR20060119871A (es) |
| CN (1) | CN1839132A (es) |
| AP (1) | AP2006003552A0 (es) |
| AR (1) | AR045388A1 (es) |
| AT (1) | ATE425977T1 (es) |
| AU (1) | AU2004268950A1 (es) |
| BR (1) | BRPI0413740A (es) |
| CA (1) | CA2536174A1 (es) |
| DE (1) | DE602004020073D1 (es) |
| IL (1) | IL173615A0 (es) |
| IS (1) | IS8318A (es) |
| MX (1) | MXPA06002019A (es) |
| MY (1) | MY138737A (es) |
| NO (1) | NO20060670L (es) |
| RU (1) | RU2006108799A (es) |
| SG (1) | SG131944A1 (es) |
| TW (1) | TW200519111A (es) |
| WO (1) | WO2005021544A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| AU2009243756B2 (en) | 2008-05-05 | 2013-06-27 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| EP2308877B1 (en) * | 2008-08-05 | 2014-01-22 | Daiichi Sankyo Company, Limited | Imidazopyridin-2-one derivatives |
| WO2010045276A2 (en) * | 2008-10-16 | 2010-04-22 | Cara Therapeutics, Inc. | Azabenzimidazolones |
| EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| DK2519522T3 (en) * | 2009-12-30 | 2014-12-08 | Arqule Inc | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| AU2012272937B2 (en) * | 2011-06-24 | 2016-09-29 | Arqule, Inc | Substituted imidazopyridinyl-aminopyridine compounds |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| ES2692243T3 (es) * | 2014-03-24 | 2018-11-30 | Arqule, Inc. | Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3H-imidazo[4,5-b]piridin-2-il)piridin-2-amina |
| EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| TW251284B (es) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| US6534535B1 (en) | 1999-08-12 | 2003-03-18 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
| US20020072530A1 (en) | 2000-02-01 | 2002-06-13 | Bing-Yan Zhu | Indole and benzimidazole inhibitors of factor Xa |
| WO2003020698A2 (en) * | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
-
2004
- 2004-08-16 AU AU2004268950A patent/AU2004268950A1/en not_active Abandoned
- 2004-08-16 EP EP04781205A patent/EP1658289B1/en active Active
- 2004-08-16 MX MXPA06002019A patent/MXPA06002019A/es unknown
- 2004-08-16 DE DE602004020073T patent/DE602004020073D1/de active Active
- 2004-08-16 WO PCT/US2004/026483 patent/WO2005021544A2/en active Application Filing
- 2004-08-16 CN CNA2004800240419A patent/CN1839132A/zh active Pending
- 2004-08-16 SG SG200702982-0A patent/SG131944A1/en unknown
- 2004-08-16 RU RU2006108799/04A patent/RU2006108799A/ru not_active Application Discontinuation
- 2004-08-16 JP JP2006523956A patent/JP2007502822A/ja active Pending
- 2004-08-16 AP AP2006003552A patent/AP2006003552A0/xx unknown
- 2004-08-16 CA CA002536174A patent/CA2536174A1/en not_active Abandoned
- 2004-08-16 BR BRPI0413740-0A patent/BRPI0413740A/pt not_active IP Right Cessation
- 2004-08-16 KR KR1020067003586A patent/KR20060119871A/ko not_active Application Discontinuation
- 2004-08-16 AT AT04781205T patent/ATE425977T1/de not_active IP Right Cessation
- 2004-08-20 TW TW093125235A patent/TW200519111A/zh unknown
- 2004-08-20 MY MYPI20043423A patent/MY138737A/en unknown
- 2004-08-20 AR ARP040103009A patent/AR045388A1/es not_active Application Discontinuation
-
2006
- 2006-02-08 IL IL173615A patent/IL173615A0/en unknown
- 2006-02-10 NO NO20060670A patent/NO20060670L/no not_active Application Discontinuation
- 2006-02-21 IS IS8318A patent/IS8318A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2006003552A0 (en) | 2006-04-30 |
| AU2004268950A1 (en) | 2005-03-10 |
| DE602004020073D1 (de) | 2009-04-30 |
| RU2006108799A (ru) | 2006-07-27 |
| BRPI0413740A (pt) | 2006-10-24 |
| ATE425977T1 (de) | 2009-04-15 |
| SG131944A1 (en) | 2007-05-28 |
| CN1839132A (zh) | 2006-09-27 |
| MXPA06002019A (es) | 2006-05-31 |
| IS8318A (is) | 2006-02-21 |
| NO20060670L (no) | 2006-05-12 |
| WO2005021544A2 (en) | 2005-03-10 |
| EP1658289B1 (en) | 2009-03-18 |
| CA2536174A1 (en) | 2005-03-10 |
| MY138737A (en) | 2009-07-31 |
| JP2007502822A (ja) | 2007-02-15 |
| WO2005021544A3 (en) | 2005-06-16 |
| TW200519111A (en) | 2005-06-16 |
| KR20060119871A (ko) | 2006-11-24 |
| EP1658289A2 (en) | 2006-05-24 |
| IL173615A0 (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045388A1 (es) | Inhibidores del c-kit imidazopiridinicos n3-sustituidos | |
| AR116993A2 (es) | Compuestos heterociclos bicíclicos y sus usos en terapia | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR070925A1 (es) | 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica | |
| AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR060768A1 (es) | Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos. | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| CO6160312A2 (es) | Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
| AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR035858A1 (es) | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 | |
| AR044342A1 (es) | Derivados de bencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |